Covenant Partners’s Halozyme HALO Stock Holding History

Covenant Partners’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,753	Closed	-$303K	–	150
2025 Q1	$303K	Buy	+4,753	New	+$276K	0.1%	106

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Covenant Partners's HALO Position: Q2 2025 in Review

Covenant Partners sold out of Halozyme (HALO) in Q2 2025, closing a stake of 4,753 shares — an estimated $303K sold.

Covenant Partners first reported a position in HALO in Q1 2025 and held it in 1 quarter. The position peaked at $303K in Q1 2025. 551 funds tracked by Wall St. Rank hold HALO as of Q2 2025.

Covenant Partners reported no remaining Halozyme position as of Q2 2025 after selling out during the quarter.
Covenant Partners sold 4,753 Halozyme shares in Q2 2025, an estimated $303K.
Covenant Partners first reported a position in Halozyme in Q1 2025 and held it in 1 quarter.
Covenant Partners's Halozyme position peaked at $303K in Q1 2025.
551 funds tracked by Wall St. Rank held Halozyme as of Q2 2025.

Based on Covenant Partners's 13F filing for Q2 2025, filed 30 Jul 2025.